Analyst Price Target is $17.20
▲ +388.64% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Vigil Neuroscience in the last 3 months. The average price target is $17.20, with a high forecast of $24.00 and a low forecast of $4.00. The average price target represents a 388.64% upside from the last price of $3.52.
Current Consensus is
Moderate Buy
The current consensus among 4 contributing investment analysts is to moderate buy stock in Vigil Neuroscience. This Moderate Buy consensus rating has held steady for over two years.
Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.
Read More
